Ciclesonide Explained

Ciclesonide, sold under the brand name Omnaris among others, is a glucocorticoid used to treat asthma and allergic rhinitis.

Side effects of the medication include headache, nosebleeds, and inflammation of the nose and throat linings.^[1]

It was patented in 1990 and approved for medical use in 2005.^[2] The drug was approved for adults and children 12 and over by the US Food and Drug Administration in October 2006.^[3] It is on the World Health Organization's List of Essential Medicines.^[4]

Society and culture

Brand names

It is marketed under the brand names Alvesco for asthma and Omnaris, Omniair, Zetonna, and Alvesco for hay fever in the US and Canada.

Further reading

• Book: Rossi S . Australian Medicines Handbook . 2006 . Adelaide . Australian Medicines Handbook . 0-9757919-2-3 .

Notes and References

1. Mutch E, Nave R, McCracken N, Zech K, Williams FM . The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue . Biochemical Pharmacology . 73 . 10 . 1657–1664 . May 2007 . 17331475 . 10.1016/j.bcp.2007.01.031 .
2. Book: Fischer J, Ganellin CR . Analogue-based Drug Discovery . 2006 . John Wiley & Sons . 9783527607495 . 488 . en.
3. Web site: FDA News Release. FDA Approves New Treatment for Allergies. 23 October 2006. Food and Drug Administration. 30 July 2009.
4. Book: ((World Health Organization)) . World Health Organization model list of essential medicines: 22nd list (2021) . 2021 . 10665/345533 . World Health Organization . World Health Organization . Geneva . WHO/MHP/HPS/EML/2021.02 . free .